Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of carboplatin and gemcitabine chemotherapy in patients with advanced ovarian cancer resistant or refractory to previous platinum chemotherapy.

Next Previous
Trial Profile

Phase II study of carboplatin and gemcitabine chemotherapy in patients with advanced ovarian cancer resistant or refractory to previous platinum chemotherapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Gemcitabine (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 10 Aug 2012 Accrual to date is 102% according to United Kingdom Clinical Research Network.
  • 17 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 12 Nov 2009 Status changed from completed to active, no longer recruiting as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top